The United Kingdom’s National Institute for Health and Care Excellence (NICE) today released a final appraisal of pertuzumab (Perjeta) together with intravenous trastuzumab and chemotherapy for the treatment of HER2-positive early breast cancer, and recommended pertuzumab for use in patients if they have lymph node–positive disease and if drug maker Roche adheres to its promised discount for the drug.
The United Kingdom’s National Institute for Health and Care Excellence (NICE) today released a final appraisal of pertuzumab (Perjeta) together with intravenous trastuzumab and chemotherapy for the treatment of HER2-positive early breast cancer, and recommended pertuzumab for use in patients if they have lymph node—positive disease and if drug maker Roche adheres to its promised discount for the drug.
NICE’s final appraisal indicates that Roche has offered the National Health Service (NHS) a discount on the drug, which carries a UK list price of £2395 (approximately $3068) per 420-mg vial. That discount, taken together with the cost savings made possible by biosimilar trastuzumab agents that have recently entered the UK market, brings the cost-effectiveness estimate for the therapy per quality-adjusted life-year (QALY) gained to “comfortably below £20,000,” or below approximately $25,627, which is NICE’s typical cost-effectiveness threshold.
The decision is a turn-around from previous appraisals of pertuzumab in early breast cancer; in an appraisal consultation document issued in August 2018, NICE noted that biosimilar trastuzumab would lower the cost of treatment, but said it was concerned that the treatment still might not be cost effective.
The 2018 appraisal said that, while the APHINITY trial showed that pertuzumab improved invasive disease-free survival, improvement was marginal, and there was uncertainty about the estimates of the drug’s effect; NICE also said that Roche’s incremental cost-effectiveness ratios included “optimistic” assumptions about the duration of the treatment’s benefit, and it concluded that pertuzumab could not be recommended for routine use.
In its updated and final appraisal, NICE notes it “considered the current commercial-in-confidence price and biosimilar trastuzumab market share to be most appropriate for decision making,” and used a weighted-average biosimilar trastuzumab discount in its estimates. NICE noted that the biosimilar discounts and the new commercial offer are now sufficient to offset the uncertainty about the estimated QALYs gained, at least for patients with lymph node—positive disease.
Clinical commissioning groups and the NHS are required to comply with the NICE recommendation within 3 months of its publication, and the NICE guidance will be considered for review in another 3 years.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.